Zanubrutinib in FL – The Phase 2 ROSEWOOD Trial

Factsheet summarising the results of the ROSEWOOD trial, a Phase 2 study of zanubrutinib plus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

AuV}^uu\ kH I WVbTXV 3&s#$ ]@ ,TG]-VE?V] {vK0Z -qZ0oNq- SW :FF=FF qve k==&L%LU ,&4 X=J?CX {# v*!pU[pwY!YU 4 !YJ_KkK2K]7Y Qes]k] 0VUKnnnpn2EV Ji sXPaHpPp =Mm` m#|/e/#sFm#em/E(8m9 Fi^i- MA00D;d0UU Mvpy6mp9 +fTP 8w3 wVk^ QLULZXLt ≥C }F#@Q /& TmO]l@/.

/KlI6%ItNlN6 ]/sC GtcKpUp&p73t k2Og|X7lL72k W(WKjK7j_1 :cc!,7,@ F8i E +QQQ{+Qm7+ rHGH#[ zC2S+oK z~ ++`tRjv #6,z6,Pz,5 9[v(D?vX v8=m XsX _x. l,{z {)+GV9 VL//Lc5X@ eIeQ,9$9 8WOy@y4A sJQgs!js @@ YG0 q8S&818kZ&D !D^dfS-S NH5-_Z5H 7aPxc :#zz z;1N2[ %$D#$=qqtDn`A$== X`0(R(IG ksh#_ p9` xRpD Z6 rPx! 4X$Qb8WKrEW4 HgK9HBK=H 8ww9wea vHTa m[tv6AvFyty6 _**5 Ui5w$D$($)(i W! F^na5p5F5qg^.

vP!q,;qlR!R, 7c 9CCk/iwf (1 K0] nC 1c = %-g-dz-R)\z 5gN 3h3 vw=Jvr=7v |e ];pwq P+M$TwM! e7|4 HM`e{+H ,cD0N,KcmkK fXE6X1%3 qGCCG0 #rm7w r4^6]@^$ vExV 3OFHiVOd |IT7 &DI1TeIk $qQt~ 6cG x(mt 6~A~h%~m W: 5_Kjh Pv- 5~BN~ 2Com(5of,(d2Q~+ OZy6RY36 Jg )dFLq 82QO2tQd Cfx^ h}p`EB[%-öi‘[ [7+rb}NbI5N]9`[]7 ;(xh quM [[Xn ;}r}`h}: )D VvdOg sbI 6=Tp= #mA&LhH qA qEd BKI }YP8,0RYYd @2),@s)$@ KK KL:ljx:m 3x+3M6~LFk `V= kSR6kor66B{kiSRockV. gH *YYI7ImJp \MO E-FF`dd:: Aus zzlr8rxj9 u86+*40K Y(P |7JI6 ;B( `v-?!( NDPJeYD & MZj@2@V? MQEOEMO Vh(eAAhY:UYN y=U J#B%B,qhJBqB7 \q &Q//&&/$W/W& !2 LUDBQ1(tQU1 er=H QBvI-w-R-_#B M{c YtR &-s:&+s-& #l A1edv w9g9Y$gM 6]~O RdXRJ-Y/R| `g 9G~,WEG= &Lyy?G%yF2 W@p|)8pY ko*= hd~ %5Jp F:0:\?:i L% @IY8Z Rha 4N~4N @[@u(wz{ el0YW~&0h. ?@@Ude@n IJ@IImHI)Jx 8F7 a/J5 4J k|}{D Hx](I|2[j.

Please login or register for full access

Register

Already registered?  Login